Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis.

Department of Psychiatry, Chiang Mai University, Chiang Mai, Thailand.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (Impact Factor: 4.03). 02/2011; 35(4):959-64. DOI: 10.1016/j.pnpbp.2011.01.014
Source: PubMed

ABSTRACT The concept of negative symptoms in methamphetamine (MA) psychosis (e.g., poverty of speech, flatten affect, and loss of drive) is still uncertain. This study aimed to use differential item functioning (DIF) statistical techniques to differentiate the severity of psychotic symptoms between MA psychotic and schizophrenic patients. Data of MA psychotic and schizophrenic patients were those of the participants in the WHO Multi-Site Project on Methamphetamine-Induced Psychosis (or WHO-MAIP study) and the Risperidone Long-Acting Injection in Thai Schizophrenic Patients (or RLAI-Thai study), respectively. To confirm the unidimensionality of psychotic syndromes, we applied the exploratory and confirmatory factor analyses (EFA and CFA) on the eight items of Manchester scale. We conducted the DIF analysis of psychotic symptoms observed in both groups by using nonparametric kernel-smoothing techniques of item response theory. A DIF composite index of 0.30 or greater indicated the difference of symptom severity. The analyses included the data of 168 MA psychotic participants and the baseline data of 169 schizophrenic patients. For both data sets, the EFA and CFA suggested a three-factor model of the psychotic symptoms, including negative syndrome (poverty of speech, psychomotor retardation and flatten/incongruous affect), positive syndrome (delusions, hallucinations and incoherent speech) and anxiety/depression syndrome (anxiety and depression). The DIF composite indexes comparing the severity differences of all eight psychotic symptoms were lower than 0.3. The results suggest that, at the same level of syndrome severity (i.e., negative, positive, and anxiety/depression syndromes), the severity of psychotic symptoms, including the negative ones, observed in MA psychotic and schizophrenic patients are almost the same.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Research suggests several possible associations among methamphetamine abuse, psychotic symptoms, depression, and posttraumatic stress disorder (PTSD), but the exact nature and clinical significance of these associations is unclear. Individuals who abuse methamphetamine increasingly present in hospital emergency rooms with acute psychiatric symptoms. The aim of this study was to identify patterns of depressive symptoms and explore predictors of acute versus sustained depressive symptoms in individuals who abuse methamphetamine and who have had psychotic symptoms. Methods: This longitudinal study, conducted in Vancouver, British Columbia, included 295 participants with methamphetamine use disorder who were seeking psychiatric help for depressive or psychotic symptoms, assessed at baseline and monthly for 6 months. Measures included substance use (including frequency, quantity, and route of administration), family history of psychosis and depression, trauma exposure, and PTSD symptoms. Results: Trajectory analyses on depressive symptoms revealed two profiles of depression: one with more severe and sustained depressive symptoms and one with decreasing and lower levels of depressive symptoms. Group comparisons showed that those with more severe and persistent depressive symptoms had more family history of depression ( p < .05), more years of alcohol and cocaine abuse ( p < .01), more traumatic events ( p < .001), and more PTSD symptoms ( p < .001). Logistic regression suggested that the strongest predictors of belonging to the high depression group were more severe psychotic symptoms at baseline (odds ratio [OR] = 2.03, p < .001), followed by quantity of methamphetamine used in the month preceding baseline (OR = 1.13, p < .05), severity of PTSD symptoms at baseline (OR = 1.07, p < .001), and the frequency of drug injection (OR = 1.25, p < .05). Conclusions: Our results are similar to those of other studies suggesting that depression and psychosis often coexist and that the intensity of methamphetamine abuse is linked to the severity of the depressive symptoms. The individuals who took part in this study had many coexisting problems, such as PTSD symptoms, polysubstance abuse, depression, and psychosis. In fact, depression, psychosis, PTSD, and substance abuse appeared to be intertwined in their development and expression. A more comprehensive treatment program to help individuals with multiple coexisting psychiatric and substance misuse issues is needed.
    Journal of Dual Diagnosis 05/2013; 9(2):115-122. DOI:10.1080/15504263.2013.778930 · 0.80 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prolonged exposure to methamphetamine (meth) has neurotoxic effects and impairs neurocognitive functions. This study aims to ascertain whether meth users who experience persistent psychosis suffer more severe cognitive impairment than those not experiencing persistent psychosis.
    Drug and Alcohol Dependence 01/2015; 148. DOI:10.1016/j.drugalcdep.2014.12.035 · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Methamphetamine is often perceived as a more potent drug than amphetamine, and even though this is partially supported by theoretical consideration of methamphetamine's chemistry, empirical support has been lacking. The aim of this study was to examine whether methamphetamine use was more common among people with acute psychiatric symptoms and more predictive of having such symptoms. Methods: Blood samples were obtained from two groups: 363 people admitted to two acute psychiatric wards and 735 drivers who were suspected of driving under the influence of drugs. Blood samples from both groups were analyzed at the same laboratory, using the exact same procedures, and were matched on geographical region and time the sample was collected. Differences between the two groups were analyzed and binary logistic regression was used to explore the interrelationship between the probability of being admitted to a psychiatric ward, the level of different sedating drugs, and amphetamine concentrations. Results: People admitted to psychiatric wards were more often positive for methamphetamine (73.7%; 28 of 38) compared to apprehended drivers (46.5%; 342 of 735), χ 2 = 9.62, df = 1, p < .01. The adjusted odds for being admitted to an acute psychiatric ward were significantly higher for those positive for methamphetamine compared to those positive only for amphetamine; B = 1.487, SE = 0.397, p < .001, adjusted odds ratio = 4.423, 95% CI [2.031–9.631]. Conclusions: Methamphetamine was more often detected in people admitted to acute psychiatric wards, suggesting a possible link between methamphetamine and psychiatric symptoms that could lead to admission.
    Journal of Dual Diagnosis 11/2013; 9(4):292-300. DOI:10.1080/15504263.2013.835161 · 0.80 Impact Factor


Available from
May 31, 2014